Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., executed a series of transactions on May 22, 2026.
• These transactions involved the exercise of stock options and the subsequent sale of common stock.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on November 7, 2025.
• This plan is set to continue until the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026, whichever comes first.
• A total of 9,500 shares were acquired through option exercise at an average price of $146.03 per share.
• Following these transactions, Rothblatt's beneficial ownership of common stock directly held is 40,513 shares, with additional holdings indirectly through a spouse, trusts, and family trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions are executed under a pre-arranged plan and do not necessarily reflect a change in the executive's confidence in the company's future performance.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating adherence to established compliance procedures for insider trading.
• The plan allows for orderly disposition of shares over time, potentially mitigating market impact.
• Martine A. Rothblatt continues to hold a significant number of shares indirectly through various trusts and her spouse, suggesting ongoing commitment to the company.

Negatives

• The sale of a substantial number of shares by a key executive could be perceived negatively by the market, despite being executed under a pre-arranged plan.
• The weighted average sale price for the disposed shares ranged from $563.05 to $569.77, indicating a significant value realized from the sales.

Risks

• The continuation of the 10b5-1 plan is contingent on the exercise of stock options, which are subject to expiration dates and potential forfeiture if not exercised.
• Future sales under the plan could continue to impact the perception of insider confidence if not balanced by other positive company developments.

Future Outlook

The 10b5-1 trading plan is active and will continue until either all 1,734,410 stock options are exercised or December 31, 2026, whichever occurs first. Further transactions may occur under this plan.

Management Comments

• The exercise of stock options and sale of resulting shares was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for various trades.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common for publicly traded companies. The use of a 10b5-1 plan by a CEO like Martine Rothblatt is a standard practice to manage personal stock sales in a compliant manner, aiming to avoid perceptions of insider trading based on material non-public information.

Stakeholder Impact

• Shareholders may interpret the sale of shares by the CEO, even under a 10b5-1 plan, as a signal of reduced insider confidence, potentially impacting share price in the short term.
• Employees holding stock options may be influenced by the executive's exercise and sale strategy, though the 10b5-1 plan itself is a standard compliance tool.

Next Steps

• Continue executing the 10b5-1 trading plan until its termination conditions are met.
• Report any further transactions in accordance with SEC regulations.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, 10b5-1 Plan, United Therapeutics, UTHR, Martine Rothblatt, Beneficial Ownership, Common Stock